Total Payments
$1.5M
2024 Payments
$123,249
Companies
9
Transactions
1,747
Medicare Patients
628
Medicare Billing
$95,799
Payment Breakdown by Category
Other$1.1M (74.8%)
Travel$198,414 (13.0%)
Consulting$153,784 (10.1%)
Food & Beverage$32,404 (2.1%)
Education$8.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 507 | 74.8% |
| Travel and Lodging | $198,414 | 672 | 13.0% |
| Consulting Fee | $153,784 | 51 | 10.1% |
| Food and Beverage | $32,404 | 515 | 2.1% |
| Education | $8.81 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Avanir Pharmaceuticals, Inc. | $528,693 | 517 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $486,048 | 643 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $376,269 | 407 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $91,795 | 150 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $19,502 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $15,125 | 13 | $0 (2024) |
| Alkermes, Inc. | $5,573 | 2 | $0 (2019) |
| Sage Therapeutics, Inc. | $5,040 | 1 | $0 (2019) |
| BioXcel Therapeutics, Inc. | $105.84 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $123,249 | 159 | Otsuka America Pharmaceutical, Inc. ($56,177) |
| 2023 | $104,209 | 115 | Neurocrine Biosciences, Inc. ($46,682) |
| 2022 | $105,708 | 114 | Neurocrine Biosciences, Inc. ($53,017) |
| 2021 | $99,740 | 104 | Neurocrine Biosciences, Inc. ($50,730) |
| 2020 | $120,939 | 152 | ACADIA Pharmaceuticals Inc ($60,595) |
| 2019 | $326,399 | 392 | Avanir Pharmaceuticals, Inc. ($138,050) |
| 2018 | $311,937 | 338 | Avanir Pharmaceuticals, Inc. ($148,616) |
| 2017 | $335,969 | 373 | ACADIA Pharmaceuticals Inc ($156,998) |
All Payment Transactions
1,747 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $98.35 | General |
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $68.44 | General |
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.91 | General |
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,538.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $554.00 | General |
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $7,752.50 | General |
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $87.00 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $6.09 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,750.00 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $806.10 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $590.44 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $227.38 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $139.79 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $6.09 | General |
| Category: Neuropsychiatry | ||||||
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $639.73 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $226.86 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $58.33 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $49.75 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $49.75 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.86 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.86 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 142 | 255 | $64,455 | $18,310 |
| 2022 | 4 | 127 | 311 | $83,994 | $22,811 |
| 2021 | 5 | 196 | 422 | $118,035 | $32,399 |
| 2020 | 5 | 163 | 277 | $80,743 | $22,280 |
Total Patients
628
Total Services
1,265
Medicare Billing
$95,799
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 32 | $17,920 | $4,387 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 41 | $11,808 | $3,762 | 31.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 59 | $11,800 | $3,626 | 30.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 88 | $9,592 | $3,331 | 34.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 35 | 35 | $13,335 | $3,204 | 24.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 42 | 192 | $38,400 | $10,431 | 27.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 30 | 30 | $16,800 | $4,628 | 27.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 55 | $15,840 | $4,421 | 27.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 34 | 34 | $12,954 | $3,332 | 25.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 53 | 247 | $50,415 | $13,988 | 27.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 51 | 52 | $29,771 | $8,180 | 27.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 47 | 52 | $20,217 | $5,319 | 26.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 59 | $17,224 | $4,764 | 27.7% |
| 99406 | Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes | Facility | 2021 | 12 | 12 | $408.00 | $148.20 | 36.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 143 | $29,601 | $8,322 | 28.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 41 | 42 | $24,402 | $6,441 | 26.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 36 | 37 | $14,652 | $4,017 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 39 | $11,544 | $3,300 | 28.6% |
| 99406 | Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes | Facility | 2020 | 16 | 16 | $544.00 | $199.78 | 36.7% |
About Dr. Jason Caplan, MD
Dr. Jason Caplan, MD is a Psychosomatic Medicine healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538196456.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Caplan, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $123,249 received in 2024. These payments were reported across 1,747 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Caplan has provided services to 628 Medicare beneficiaries, totaling 1,265 services with total Medicare billing of $95,799. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychosomatic Medicine
- Other Specialties Psychiatry
- Location Phoenix, AZ
- Active Since 06/27/2006
- Last Updated 12/13/2024
- Taxonomy Code 2084P0015X
- Entity Type Individual
- NPI Number 1538196456
Products in Payments
- NUEDEXTA (Drug) $573,985
- INGREZZA (Drug) $486,048
- NUPLAZID (Drug) $376,269
- REXULTI (Drug) $33,409
- COBENFY (Drug) $5,538
- ARISTADA (Drug) $5,400
- ZULRESSO (Drug) $5,040
- Nuedexta (Drug) $3,187
- Aristada 441 mg (Drug) $173.40
- IGALMI (Drug) $105.84
- ABILIFY MYCITE (Drug) $38.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.